Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.
The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
